- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 16th, 2007
By Jack Uldrich August 16, 2007
While reading an interesting article about the link between academic research and commercial products, I stumbled upon an intriguing company experimenting with a novel -- and tiny -- new way to fight cancer.
Insert Therapeutics, a subsidiary of Arrowhead Research (Nasdaq: ARWR), specializes in developing promising nanotechnology-related university research. It seems that Insert Therapeutics is focusing on an innovative new nanotech-based platform for the treatment of cancer, and it's helping to shepherd the platform through the FDA clinical phase process. The drug in question is only in phase 1 of FDA trials, so it still has a long way to go, and there's absolutely no guarantee that it will ever receive final approval.
|Related News Press|
Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016
Arrowhead to Present at Upcoming March Conferences March 1st, 2016
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers